Development of CAR T cells designed to improve antitumor efficacy and safety Journal Article

   


Authors: Jaspers, J. E.; Brentjens, R. J.
Article Title: Development of CAR T cells designed to improve antitumor efficacy and safety
Abstract: Chimeric antigen receptor (CAR) T cell therapy has shown promising efficacy against hematologic malignancies. Antitumor activity of CAR T cells, however, needs to be improved to increase therapeutic efficacy in both hematologic and solid cancers. Limitations to overcome are ‘on-target, off-tumor’ toxicity, antigen escape, short CAR T cell persistence, little expansion, trafficking to the tumor and inhibition of T cell activity by an inhibitory tumor microenvironment. Here we will discuss how optimizing the design of CAR T cells through genetic engineering addresses these limitations and improves the antitumor efficacy of CAR T cell therapy in pre-clinical models. © 2017
Keywords: cytokines; genetic engineering; chimeric antigen receptor; costimulation; tumor microenvironment; armored car t cells
Journal Title: Pharmacology & Therapeutics
Volume: 178
ISSN: 0163-7258
Publisher: Elsevier Inc.  
Date Published: 2017-10-01
Start Page: 83
End Page: 91
Language: English
DOI: 10.1016/j.pharmthera.2017.03.012
PROVIDER: scopus
PMCID: PMC5601024
PUBMED: 28342824
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016554390&doi=10.1016%2fj.pharmthera.2017.03.012&partnerID=40&md5=da5aed1e009ae55f63459ccb6626b05b
Notes: Review -- Export Date: 4 October 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Janneke Elisabeth Jaspers
    3 Jaspers
Related MSK Work